Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
Cellectar Biosciences, Inc. (CLRB) will release its financial results for the year ended December 31, 2023, on March 27, 2024. The company, specializing in cancer treatment drugs, will host a conference call at 8:30 am Eastern Time to discuss the results with investors.
03/20/2024 - 06:40 AM
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
Conference call & Webcast Details: Date: Wednesday, March 27 Time: 8:30 am Eastern Time Toll Free: 1-888-886-7786 Webcast: Click HERE Call meTM : Click HERE
Participants may use the dial-in numbers above and be answered by an operator OR click the Call meTM link for instant telephone access to the event. The Call meTM link will be made active 15 minutes prior to the scheduled start time.
A replay of the call will be available on Events section of the company’s investor relations website.
About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter , LinkedIn , and Facebook .
Contacts
MEDIA: Claire LaCagnina Bliss Bio Health 315-765-1462clacagnina@blissbiohealth.com
INVESTORS: Chad Kolean Chief Financial Officerinvestors@cellectar.com
When will Cellectar Biosciences release its financial results for the year ended December 31, 2023?
Cellectar Biosciences will release its financial results on March 27, 2024.
What is Cellectar Biosciences' ticker symbol?
Cellectar Biosciences' ticker symbol is CLRB.
What is the focus of Cellectar Biosciences as a company?
Cellectar Biosciences is focused on the discovery, development, and commercialization of drugs for the treatment of cancer.
When will the conference call with investors take place?
The conference call with investors will take place on Wednesday, March 27, 2024, at 8:30 am Eastern Time.
How can participants access the conference call?
Participants can dial the toll-free number 1-888-886-7786 or click on the Call meTM link for instant telephone access to the event.
Cellectar Biosciences Inc
CLRB Rankings
#1026 Ranked by Stock Gains
CLRB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Florham Park
About CLRB
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p